abstract |
The present disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by using IL-17 antagonists in a patient population defined by serum concentrations of IgE and optionally also eosinophil counts in peripheral blood. It is about. |